SESN Overview
Upcoming Projects (SESN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (SESN)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (SESN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (SESN)
-
Eleven Bio (EBIO) Expects Topline Phase III Data for Vicinium in High Grade Non-Muscle Invasive Bladder Cancer in H1 2018
Tickers: EBIO, Viventia Bio, SESN
Occurred on: May 21, 2018 -
Sesen Bio (SESN) to Initiate Phase 2 Trial for Proxinium in Treatment of Late-Stage Squamous Cell Carcinoma of Head and Neck in H1 2017
Tickers: EBIO, SESN
Occurred on: Nov 20, 2017 -
Eleven Biotherapeutics (EBIO) Acquires Canadian Viventia Bio in All-Stock Deal
Tickers: EBIO, Viventia Bio, SESN
Occurred on: Sep 21, 2016 -
Eleven Biotherapeutics Announces Effectiveness of Investigational New Drug Application for EBI-031
Tickers: EBIO, SESN
Occurred on: Jul 07, 2016 -
Eleven Biotherapeutics Announces Investigational New Drug Application Submission to Initiate Clinical Trials of EBI-031 for Ocular Diseases
Tickers: EBIO, SESN
Occurred on: Jun 13, 2016 -
Phase 3 data of Isunakinra (EBI-005) for Moderate to severe allergic conjunctivitis due 1Q 2016
Tickers: EBIO, SESN
Occurred on: Jan 15, 2016
Strategic Initiatives (SESN)
-
Eleven Biotherapeutics Completes Exclusive Licensing Deal for IL-6 Antagonist Antibody Technology, Including EBI-031
Tickers: EBIO, SESN
Announcement Date: Aug 16, 2016 -
Eleven Biotherapeutics Announces Signing of Exclusive License Agreement
Tickers: EBIO, RHHBY, SESN
Announcement Date: Jun 13, 2016
